RA Capital jumps aboard nine-figure round for the endocrine biotech co-founded by Humalog inventor
In the summer of 2020, a successful scientist/investor team took the wraps off their latest project in MBX Biosciences. But at the time, they left most granular details up to the imagination.
On Monday, MBX revealed what it’s been working on and how it plans to move forward.
The biotech, helmed by CEO Kent Hawryluk and his longtime business partner and CSO Richard DiMarchi, closed a $115 million Series B round Monday, led by Wellington Management. RA Capital — the Peter Kolchinsky/Rajeev Shah-led firm with a knack for steering quick Nasdaq leaps — also chipped in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.